Centiva Capital, LP Novavax Inc Call Options Transaction History

Centiva Capital, LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$8.86 - $25.04 $8,860 - $25,040	-1,000 Reduced 5.29%	17,900 $184,000
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $309,400 - $1.29 Million	17,000 Added 894.74%	18,900 $345,000
Q2 2022 Aug 17, 2022	SELL	$36.28 - $75.29 $181,400 - $376,450	-5,000 Reduced 72.46%	1,900 $97,000
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $62,757 - $128,610	-900 Reduced 11.54%	6,900 $508,000
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $929,809 - $1.51 Million	6,910 Added 776.4%	7,800 $1.12 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $1.44 Million - $2.19 Million	-8,110 Reduced 90.11%	890 $184,000
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $1.09 Million - $2.32 Million	9,000 New	9,000 $1.91 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.